Institutional investors purchased a net $3.8 million shares of HALO during the quarter ended March 2013, and now own 46.39% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Mutual fund holders | 27.28% |
| Individual stakeholders | 23.85% |
| Other institutional | 19.11% |